Acute and chronic renal failure

Journal of the American Podiatric Medical Association

Volumn 94, Issue 2, 2004, Pages 168-176

  Costa, Jonathan ^a   Crausman, Robert S ^a,b   Weinberg, Marc S ^c  

^a MEMORIAL HOSPITAL OF RHODE ISLAND   (United States)

^b RHODE ISLAND DEPARTMENT OF HEALTH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOPAMINE; FUROSEMIDE; GLUCONATE CALCIUM; INSULIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; VASOPRESSIN;

ACIDOSIS; ACUTE KIDNEY FAILURE; BLEEDING; BLOOD VOLUME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COMORBIDITY; CREATININE CLEARANCE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE CALCULATION; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL DISEASE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LACTIC ACIDOSIS; LUNG DISEASE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERITONEAL DIALYSIS; PODIATRY; POTASSIUM INTAKE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; UREMIA;

EID: 1842685079     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/87507315-94-2-168     Document Type: Review

References (18)

1. LINDEMAN RD, TOBIN J, SHOCK NW: Association between blood pressure and the rate of decline in renal function with age. Kidney Int 26: 861, 1984.
2. RODRIGUEZ-PUYOL D: The aging kidney. Kidney Int 54: 2247, 1998.
3. THADHANI R, PASCUAL M, BONVENTRE JV: Acute renal failure. N Engl J Med 334: 1448, 1996.
4. HOU SH, BUSHINSKY DA, WISH JB, ET AL: Hospital-acquired renal insufficiency: a prospective study. Am J Med 74: 243, 1983.
5. KAUFMAN J, DHAKAL M, PATEL B, ET AL: Community-acquired acute renal failure. Am J Kidney Dis 17: 191, 1991.
6. SHUSTERMAN N, STROM BL, MURRAY TG, ET AL: Risk factors and outcome of hospital-acquired acute renal failure: clinical epidemiologic study. Am J Med 83: 65, 1987.
7. NOVIS BK, ROIZEN MF, ARONSON S, ET AL: Association of preoperative risk factors with postoperative acute renal failure. Anesth Analg 78: 143, 1994.
8. CORWIN HL, TEPLICK RS, SCHREIBER MJ, ET AL: Prediction of outcome in acute renal failure. Am J Nephrol 7: 8, 1987.
9. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39 (suppl 1): S1, 2002.
10. ALLON M: Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol 6: 1134, 1995.
11. DELMEZ JA, SLATOPOLSKY E: Hyperphosphatemia: its consequences and treatment in chronic renal failure. Am J Kidney Dis 19: 303, 1992.
12. ALPERN RJ, SAKHAEE K: Clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. Am J Kidney Dis 29: 291, 1997.
13. CORESH J, ASTOR BC, GREENE T, ET AL: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1, 2003.
14. ADAMSON JW, ESCHBACH JW: Erythropoietin for end-stage renal disease. N Engl J Med 339: 625, 1998.
15. EBERST ME, BERKOWITZ LR: Hemostasis in renal disease: pathophysiology and management. Am J Med 96: 168, 1994.
16. WEINBERG MS, WEINBERG AJ, ZAPPE DH: Effectively targeting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst 1: 217, 2000.
17. WEINBERG MS, WEINBERG AJ, CORD R, ET AL: The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion. J Renin Angiotensin Aldosterone Syst 2: 196, 2001.
18. TEPEL M, VAN DER GIET M, SCHWARZFELD C, ET AL: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343: 180, 2000.